Helius Medical Technologies, Inc. — 2019 Form 10-K
Filing identity: The supplied filing is Helius Medical Technologies, Inc. (Nasdaq: HSDT), not Solana Co. It covers the fiscal year ended December 31, 2019, rather than a standalone 2019 fourth quarter.
Business context and reporting period
Helius is a development-stage neurotechnology company focused on its PoNS device, a non-invasive tongue-based neurostimulator used with therapy. At year-end, PoNS was authorized in Canada for a 14-week treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI). It was not authorized for commercial sale in the U.S., EU, or Australia. The company began Canadian commercialization in March 2019 and acquired its Canadian commercial partner, Heuro, in October.
Financial performance and liquidity
| Metric (USD, millions unless stated) | 2019 | 2018 |
|---|---|---|
| Revenue | 1.50 | 0.48 |
| Gross profit | 0.65 | 0.48 |
| Gross margin | 43.4% | Not meaningful; no product cost of sales reported |
| Operating expenses | 24.65 | 27.15 |
| Operating loss | (24.00) | (26.68) |
| Net loss | (9.78) | (28.62) |
| Cash used in operating activities | (21.00) | (19.62) |
| Cash at year-end | 5.46 | 25.58 |
| Working capital | 3.44 | 22.76 |
2019 revenue was mainly PoNS device sales in Canada ($1.45 million); 2018 revenue was primarily a one-time license fee. The 2019 net loss included a $14.11 million non-cash gain from remeasuring derivative warrant liabilities, versus a $3.58 million loss in 2018. The improvement in reported net loss therefore does not indicate operating profitability. Operating cash use increased despite lower operating expenses.
Total liabilities were $4.51 million, including $0.64 million of operating lease liabilities and $0.25 million of deferred revenue. The balance sheet reports no conventional borrowings. The company raised $1.7 million gross, or $1.1 million net, in a November 2019 share offering, issuing 4.82 million shares at $0.35 per share. Shares outstanding at year-end were 30.72 million.
Material changes versus 2018
- Revenue rose to $1.50 million from $0.48 million, shifting from mainly license revenue to Canadian device sales.
- Research and development expense fell by $1.88 million, primarily as device development concluded; selling, general and administrative expense declined by $0.69 million.
- Cash declined by $20.12 million during 2019, compared with a $20.02 million increase in 2018, when the company had raised substantially more financing.
- The Heuro acquisition changed the Canadian commercialization model and added goodwill and intangible assets; consideration was approximately $1.6 million.
- Management reduced its workforce by more than 30% amid the delayed U.S. regulatory timeline.
Outlook, risks and unusual items
- Funding and going concern: Management and the auditor cited substantial doubt about the company’s ability to continue as a going concern. The company said year-end cash was insufficient to fund operations beyond May 2020 without additional capital. It warned that failure to raise funds could force reduced operations, asset sales, or cessation of operations.
- U.S. regulatory path: FDA denied the 2018 mmTBI de novo request in April 2019, citing insufficient evidence to separate the device’s contribution from physical therapy. The planned TBI-002 trial was designed to compare physical therapy plus PoNS with physical therapy alone in 103 subjects. Management estimated enrollment would begin in April 2020 and trial completion and FDA submission in Q2 2021; these were estimates, not guarantees.
- Other markets and indications: Helius planned a U.S. submission for an MS indication in the second half of 2020 and submitted a Canadian MS label-amendment application in February 2020. Its EU application was withdrawn in August 2019 amid regulatory and notified-body uncertainty. The Australian application remained under review.
- Commercial and reimbursement risk: Canadian sales were early-stage, and broad reimbursement was not established. Management expected U.S. government and commercial payer coverage could take at least 24 months after authorization. Initial U.S. sales, if authorized, could depend on patients paying out of pocket.
- Clinical evidence: Prior mmTBI trials reported balance improvements, but the FDA’s denial underscores that the existing evidence did not establish the device’s independent treatment effect to the agency’s satisfaction.
- Litigation and controls: Two putative shareholder class actions alleged misleading statements about FDA prospects; outcomes were not predictable. A 2019 business-email compromise caused a loss of approximately $0.1 million, with no recovery reported at filing. Management identified a material weakness in payment controls and described enhancements; it nevertheless concluded internal control over financial reporting was effective at year-end.
- Other exposures: The company depends on outside manufacturers and a limited workforce, faces potential dilution from future equity financing, and reported no material debt but has lease commitments and ongoing operating cash needs.
Most important facts for investors to verify
- Subsequent financing, cash runway, and any change in going-concern status after the March 12, 2020 filing date.
- Actual Canadian PoNS sales, patient volumes, clinic utilization, collections, and gross margins; reported revenue alone does not establish repeatable demand.
- FDA feedback, TBI-002 enrollment and results, and whether management’s stated submission timelines were achieved.
- Regulatory decisions on the Canadian MS application and Australian submission, and any renewed EU filing.
- Reimbursement coverage, pricing, and patient affordability, including the effect of the 2020 pricing changes.
- Progress and potential financial impact of the shareholder litigation, cyber-loss recovery, and remedial payment-control measures.